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Abstract 11	  
Hollow fibre membrane bioreactors (HFB) provide a novel approach towards tissue engineering 12	  
applications in the field of regenerative medicine. For adherent cell types HFBs offer an in vivo-like 13	  
microenvironment as each fibre replicates a blood capillary and mass transfer rate across the wall is 14	  
independent from the shear stresses experienced by the cell. HFB also possesses the highest surface 15	  
area to volume ratio of all bioreactor configurations. In theory these factors enable a high quantity of 16	  
the desired cellular product with less population variation, and favourable operating costs. 17	  
Experimental analyses of different cell types and bioreactor designs show encouraging steps towards 18	  
producing a clinically relevant device. This review discusses the basic HFB design for cell expansion 19	  
and in vitro models; compares data produced on commercially available systems and addresses the 20	  
operational differences between theory and practice. HFBs are showing some potential for 21	  
mammalian cell culture but further work is needed to fully understand the complexities of cell culture 22	  
in HFBs and how best to achieve the high theoretical cell yields. 23	  
 24	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Introduction  27	  
The requirement to culture mammalian cells in large quantities and in an in vivo-like environment has 28	  
led to the application of a wide range of different bioreactor configurations based on traditional 29	  
biochemical engineering designs. One bioreactor type that is showing promise is the hollow fibre 30	  
membrane bioreactor (HFB); this configuration has been applied across all tissue engineering 31	  
applications (TE-apps), i.e. cell expansion for regenerative medicine (Gundersen et al. 2010; Nold et 32	  
al. 2013; Roberts et al. 2012), cell-scaffold constructs for regenerative medicine from injectable cell-33	  
gel composites  (Seliktar 2012; Shin et al. 2013; Vermonden et al. 2012) and large bone defect 34	  
augmentation (Niemeyer et al. 2010; Soardi et al. 2011; Torres et al. 2011), to  cell delivery after 35	  
myocardial infarction (Bernstein and Srivastava 2012; Roberts et al. 2012; Usuludin et al. 2012); and 36	  
bioartificial organs   (Oh et al. 2010; Oo et al. 2011); in vitro/toxicology models (Usuludin et al. 2012; 37	  
Zhang et al. 2012), and most recently cultured meat, in the author’s lab.  38	  
Relatively simple scale-up is theoretically possible with HFBs, compared to other bioreactor 39	  
configurations, as scale-up can be based on Krogh cylinder modelling. The current trend for 40	  
companies utilising TE-apps, when developing high quality cost effective bioprocesses, is to 41	  
incorporate stirred tank bioreactors, which are traditionally and successfully used for the large-scale 42	  
production of biopharmaceuticals. Despite the sensible lateral application of this configuration to TE-43	  
apps, the complexity of tissues and the sensitivity of mammalian cells to subtle changes to their 44	  
environment has driven the design of a second generation of bioreactors to meet the biological, 45	  
financial and regulatory requirements to enable mass-production to meet global demands.  46	  
Given the breadth of TE-apps where the final product from a cell expansion process will range from 47	  
undifferentiated stem cells to a tissue-like cell-scaffold construct, it is unlikely there will be a single 48	  
bioreactor type that exhibits broad utility, as the stirred tank has done for biopharmaceutics. Not only 49	  
will the cell type(s) and required extent of differentiation vary, but so will the downstream processing 50	  
step of removing the product, purifying it and packaging it for delivery and application in the clinic.  51	  
As such HFBs are not suited to all tissues and all applications and the tissue engineer should choose 52	  
the bioreactor configuration only once the product is fully understood. Herein HFBs are reviewed in 53	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the context of the applications for which they are particularly suited – as devices for cell expansion 54	  
and as in vitro models. 55	  
 56	  
HFBs for Regenerative Medicine Applications 57	  
The versatility of the HFB is owed to the ease at which environmental changes can be applied to the 58	  
system. For example if used as a device for cell expansion the researcher would focus on applying the 59	  
optimum conditions to accelerate rates of cell growth and cell number. Other practical considerations 60	  
include the removal and extraction of the cells from the bioreactor once the desired number of cells is 61	  
met. For a regenerative medicine construct, multiple cell types may be used (particularly when 62	  
modelling heterogeneous tissues), and the fibres may be used to deliver drugs or growth factors to 63	  
improve endogenous tissue regeneration. Cells can be cultured on the internal or external surfaces of 64	  
the hollow fibre, as well as be suspended in a gel in the extracapillary space (ECS) (Figure 1). 65	  
 FIGURE 1 PLACED HERE 66	  
HFBs for cell expansion 67	  
Given their design, HFBs have the potential to expand a population of cells to a clinically significant 68	  
number and enable the differentiation of stem cells along desired lineages. These properties make 69	  
HFBs an attractive prospect for regenerative medicine. To support this statement, a variety of cell 70	  
types have already been successfully expanded (Table 1) and differentiated (Table 2) using the HFB 71	  
system.  72	  
 TABLE 1 AND TABLE 2 PLACED HERE 73	  
Several methods are available for determining the efficacy of cellular expansion. These methods 74	  
include (i) direct quantification of seeding and harvesting cell numbers or densities (ii) indirectly 75	  
quantifying by comparing changes in DNA, glucose or lactate concentrations over time or (iii) 76	  
qualitatively depicting changes through imaging. These methods are not entirely comparable, 77	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particularly where the result has not been quantified. Therefore, it is not possible to directly determine 78	  
differences in efficacy between various experimental systems in the literature. A standardised direct 79	  
quantitative method of cell growth alongside supplementary methods of determining cellular 80	  
expansion  would allow for efficient comparisons between HFB setups. 81	  
 82	  
While the HFB system could potentially generate a renewable cell source at therapeutically significant 83	  
levels, problems with producing clinically useful cells include maintaining population heterogeneity 84	  
during the culture process (Williams et al. 2012) and the requirement of having to produce yields 85	  
approximating 105 to 1013 cells per dose (Simaria et al. 2014). Therefore, it is important to identify 86	  
how bioreactor design, culture conditions and scale-up can be improved to achieve the standards 87	  
required for therapeutic use. 88	  
 89	  
HFBs for regenerative medicine constructs 90	  
A three dimensional (3D) culture scaffold wherein the HFB contains a gel or cells cultured on hollow 91	  
fibres are assembled sufficiently close to allow bridging holds a number of advantages over traditional 92	  
two dimensional (2D) cultures grown in tissue culture flasks. 3D culture substrates are able to better 93	  
represent the in vivo environment such that cell phenotype, gene expression and function are 94	  
improved compared to the 2D environment; this is due to complex cellular interactions that occur 95	  
between cells and the extracellular matrix (ECM) (Sun et al. 2006; Zhou et al. 2008).  96	  
Cells can be cultured on the intraluminal wall of hollow fibre membranes. This has been demonstrated 97	  
with alveolar epithelial cells, where an air-liquid interface similar to that in lung tissue was 98	  
reproduced by passing air through the fibre lumen (Grek et al. 2009). Endothelial cells constitute the 99	  
inner surface of the vasculature.  While they do not form tight junctions under 2D culture conditions, 100	  
when cultured on the lumen surface and exposed to the shear stresses of media flow through the 101	  
lumen, (similar to the flow of blood in vessels) they behave in a similar fashion to that seen in vivo 102	  
(Ott and Ballermann 1995). The issue with this approach is that the mass transfer rate to the cells in 103	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the ECS is now coupled to the shear stress experienced by the endothelial cells which may limit the 104	  
feed flow rates used. Yamazoe and Iwata (2006) showed that culturing cells within the fibre lumen 105	  
could potentially protect the cells from rejection by the host immune system if they were implanted 106	  
into a patient, due to the ability to control the molecular weight cut off of the semipermeable 107	  
membrane. 108	  
 109	  
HFBs for use as in vitro models 110	  
In vitro models allow for the study of tissue function, as well as drug discovery and toxicology 111	  
testing, and metabolism analysis without the need for using animal models; the same considerations 112	  
can be applied to bioartificial organs but these are not reviewed here in detail. The HFB setup has 113	  
been utilised in bioartificial organ design to replicate liver (Gautier et al. 2009) and kidney functions 114	  
(Oo et al. 2011) with the intent of utilisation as clinical therapy. In the case of drug and toxicology 115	  
testing, repeated dosage, acute and chronic effects may be examined depending on how long the 116	  
model is maintained (Zeilinger et al. 2011).  However, there are certain considerations associated with 117	  
creating a system that is able to replicate the in vivo setting successfully, such as the interactions 118	  
between different cell types and culture conditions that exactly match those found in vivo so that 119	  
accurate extrapolation of data can be made. Furthermore, high cell growth rates may not be desirable 120	  
once the cells have formed the model construct, instead requiring conditions that facilitate the desired 121	  
cell number at a stationary phase but not their growth phase.  122	  
 123	  
Physical control of the environment is relatively easy as the membrane characteristics, flow rates and 124	  
mass transfer rates can be prescribed, however the biological environment in terms of the culture 125	  
media is also of importance but is very complex. Basic culture medium conditions provide cells with 126	  
the nutrients and growth factors specific to their environment to thrive. The medium can be further 127	  
supplemented with growth factors and cytokines to aid proliferation and differentiation depending on 128	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the requirements. pH may be controlled through the addition of an appropriate buffer or by careful 129	  
assessment in media containing the indicator phenol red. Foetal bovine serum can also be added to the 130	  
culture medium to allow deposition of surface proteins, aiding attachment of adherent cultures. The 131	  
addition of antibiotics and antifungals can reduce the likelihood of infection within the closed system 132	  
of the bioreactor. However, artificial culture media do not necessarily provide an exact replica of the 133	  
types of nutrients (and the appropriate concentration) and gas seen physiologically which could affect 134	  
cellular functions.  135	  
Whole blood has been utilised in HFB as the culture medium equivalent to in vivo conditions, to 136	  
provide both nutrients and oxygenation to the cells whilst removing waste products. This route has 137	  
drawbacks due to a lack of a supply of constant comparable blood, strict regulations for safe use, 138	  
fouling by blood cell attachment to the membrane, and clotting. A compromise is to separate the red 139	  
blood cells from whole blood and use them to supplement the chosen culture medium, thus preventing 140	  
immune responses (Gundersen et al. 2010; Sullivan et al. 2007) or to add an anticoagulant to the 141	  
system, either in the medium or coating the intraluminal surface to reduce thrombogenicity (Zhang et 142	  
al. 2012). A study by Chen and Palmer (2010) added bovine haemoglobin to the culture medium in a 143	  
HFB to act as an oxygen carrier. This showed a higher cell mass, improved efficiency of hepatocyte 144	  
metabolism and drug detoxification, and conservation of albumin synthesis , and ammonia 145	  
detoxifying functions compared to controls.  Oxygen requirements vary between cell types, for 146	  
example hepatocytes have different functions depending on oxygen concentration based upon their 147	  
location on the portovenous axis, a phenomenon known as liver zonation (Burke and Tosh 2006; 148	  
Davidson et al. 2012). Mathematical modelling of oxygen transport, and application of the 149	  
mathematical models to the oxygen transport in laboratory settings (Davidson et al. 2012; Patzer 150	  
2004) as well as control of operating parameters (Shipley et al. 2011), is an important component of 151	  
HFB in vitro model design.  152	  
 153	  
Common design aspects and basic operation of HFBs 154	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HFB configuration and operation 155	  
The configuration of a HFB provides a greatly increased surface area for cellular attachment and 156	  
proliferation, in comparison to other bioreactor configurations. HFBs only require a volume that is 157	  
0.1% the capacity of a T-flask, or 0.5% the size of a stirred tank to grow an equivalent number of cells 158	  
(Table 3) (Ellis et al. 2005). The culture parameters within the HFB must also be considered to ensure 159	  
that they produce large cell yields and high viability without loss of phenotype; it is therefore very 160	  
important that the physical, chemical and biological environment within the bioreactor is as close as 161	  
possible to the in vivo environment and the HFB should be tailored to each cell type or types; attempts 162	  
have been made to do this based on oxygen requirements for different cell types using computational 163	  
fluid dynamics (Shipley et al. 2011). The semipermeable nature of the hollow fibre membrane is 164	  
conducive to selective diffusion between media flowing through the fibre lumen and cells in the ECS, 165	  
and the flux of media across the membrane can be prescribed based on membrane and bioreactor 166	  
physical properties (Shipley et al. 2010). By culturing the cells in the ECS, shear stresses are 167	  
decoupled from the bulk media flow in the lumen thus preventing cell damage, detachment from the 168	  
culture substrate and undesirable shear stress responses. It should be noted however that a second 169	  
media stream can be passed through the ECS if desired. Figure 2 shows several different 170	  
configurations of HFBs. The important parameters to be controlled are the temperature, the flow rate 171	  
of the media through the lumen, pH, the pressure differentials across the bioreactor, and dissolved 172	  
oxygen, nutrient, waste product and metabolite concentrations and residence times. Other properties 173	  
intrinsic to the fibre itself are also important to consider. For example, when culturing a desired cell 174	  
number a bundle of fibres of a suitable length and diameter are necessary to provide the correct 175	  
surface area for growth.   176	  
 TABLE 3 PLACED HERE 177	  
 FIGURE 2 PLACED HERE 178	  
Hollow fibre membrane fabrication and properties 179	  
The macroarchitecture of the hollow fibre membrane provides a highly permeable, minimally resistant 180	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barrier that acts as a scaffold for adherent cells. The hollow fibre membranes used in HFBs for TE-181	  
apps are usually made from a polymer, the fibre being fabricated using dry-wet or wet-wet spinning 182	  
(Ellis and Chaudhuri 2007). This produces a porous fibre with a hollow core, the lumen, through 183	  
which cell medium can flow. Structural, mechanical and topographical factors are dependent on the 184	  
manufacture of the fibre itself, including the type of polymer used, the solvent and nonsolvent 185	  
selection, the phase inversion process it has undergone, and any coating applied (Ellis and Chaudhuri 186	  
2007). For example, pore size can be modified by altering the initial casting dope solution (Ellis and 187	  
Chaudhuri 2008) to allow the selective passage of specific cellular products through the porous 188	  
polymer matrix based on their molecular weight. Careful selection of fibre fabrication conditions, 189	  
alongside the selected operating conditions, ensures good mass transfer of nutrients and oxygen 190	  
throughout the construct.  191	  
The hollow fibre biomaterial should also be biocompatible. Whether the surface is a suitable 192	  
environment for cell adherence is further influenced by several factors; in vivo this is achieved 193	  
through interaction between cell adhesion receptors such as integrins and the ECM. In the in vitro 194	  
setting, these interactions can be affected by the surface energy and topography of the biomaterial 195	  
surface (De Bartolo et al. 2002). A hydrophilic surface is more conducive to cell attachment due to the 196	  
ability for proteins within culture media serum to adsorb on to the biomaterial. Modification of the 197	  
biomaterial surface to mediate the biochemical signalling required for cell-matrix interactions can be 198	  
achieved through surface treatment, such as plasma treatment for the addition of functional groups to 199	  
increase hydrophilicity (Jacobs et al. 2012), or surface grafting of bioactive molecules, thus allowing 200	  
interaction between the cells and the added molecules rather than the polymer surface (Bellis 2011). 201	  
Alternatively, the ECS can also be filled with a gel to mimic the ECM. Immobilisation of cells in 202	  
sodium alginate has previously shown increased induction of vasculogenesis of human embryoid 203	  
bodies from human embryonic stem cells when compared to static or rotating bioreactor setups 204	  
(Gerecht-Nir et al. 2004). In addition, the use of alginate to immobilise primary porcine pancreatic 205	  
cells in a HFB setup demonstrated increased intracellular insulin compared to suspension cultures 206	  
(Hoesli et al. 2009).  207	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The exact setup and operation of the HFB clearly depends on the tissue and the application, however 208	  
there are a number of common considerations for their use. Figure 3 presents a generalised flow chart 209	  
for cell culture in HFBs. 210	  
FIGURE 3 PLACED HERE 211	  
 212	  
The Design and Application of Commercially-Available HFBs  213	  
Due to the advantages of growing cells in 3D structures, various research groups have strived to 214	  
develop their own HFB systems. Others have developed HFBs into commercial brands, providing a 215	  
variety of products with dimensions, separation properties and material types to suit numerous 216	  
laboratory-testing applications. Some of the companies who sell bench scale HFBs are Fibercell 217	  
Systems, Spectrum Labs, Terumo BCT and Eurotechnologies. The equipment provided by these three 218	  
companies has been used in a small number of published articles for physical experimentation 219	  
(FiberCell) (Usuludin et al. 2012) and used as a base for mathematical modelling (Spectrum Labs) 220	  
(Chen and Palmer 2009).   221	  
Fibercell primarily produce hollow fibres made from polysulfone with the surface areas between 75 222	  
cm2 and 2.5 m2 with increasing ECS volume of 12 ml to 150 ml and a 50% packing density within a 223	  
reactor housing made from glass. The additional surface area allows a greater number of cells to grow 224	  
on and within the fibres, a maximum of 109 – 1011 over the range of HFB sizes. Molecular weight cut 225	  
off (MWCO) ranges from 5 kD and 0.1µm and flow rates up to 200 ml min-1 can be applied. This 226	  
system is advertised to produce monoclonal antibodies and secreted proteins in high concentrations, to 227	  
expand lymphocytes and endothelial cells, and to be used for in vitro toxicology tests (FiberCell 228	  
2014). 229	  
The HFBs sold by Spectrum Labs (brand name ‘Cellmax’) offer a wider range of materials: 230	  
polysulfone, polypropylene, polyethylene, and regenerated cellulose. It recommends the most suitable 231	  
polymer depending on the application: hollow fibres made from polysulfone if required to collect 232	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secreted cell products, or made from either polypropylene or polyethylene for experimentation on 233	  
cellular adhesion and gas diffusion (Spectrum Laboratories 2012). Pore sizes between 10 kD and 0.5 234	  
µm are available, and their HFBs allow a flow rate between 5-120 ml min-1 through the lumen of 235	  
fibres with Reynolds numbers of less than 10 and velocities of 10-4 -10-2 ms-1 depending on membrane 236	  
size. Side ports are also included in this system to allow for a secondary flow through the ECS if 237	  
required.  238	  
It could be argued that the presence of market leaders in lab scale HFB systems could allow parallels 239	  
to be drawn between different research groups who use the same commercially available equipment, 240	  
providing some sort of standard by which data could be compared. However in the process of writing 241	  
this review only a handful of publications have actually used commercial HFB products, with many 242	  
groups opting to make their own hollow fibres.  If it can be demonstrated that a commercial HFB 243	  
system could be constructed from materials of a known standard, and built using automated 244	  
manufacturing techniques, a commercial system may prove advantageous for larger collaborative 245	  
research projects and clinical utility to ensure consistency. 246	  
 247	  
Theoretical Promises versus Actual Success and Current Issues with HFBs  248	  
The use of the commercial systems outlined above has been documented in journal articles, allowing 249	  
data to be generated to check the claims reported in the catalogues of their manufacturers. A HFB 250	  
cartridge purchased from Fibercell Systems was used (model C2011) to grow a co-culture of stromal 251	  
and erythroleukaemia cells, of which 4.4 x 108 were successfully harvested from the HFB  (Usuludin 252	  
et al. 2012). This is almost an order of magnitude less than the advertised maximum cell number of 253	  
109. The authors describe how a complete cell harvest was not achievable because some cells 254	  
remained trapped between fibres, an issue which would arise in any tightly packed HFB. This 255	  
harvesting issue of course is not a problem for hollow fibre membrane constructs designed for 256	  
implantation.  257	  
The hollow fibre construct can also be a disadvantage because it does not allow the direct real time 258	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visual inspection of cellular growth within the porous hollow fibre network, instead resorting to more 259	  
indirect methods such as mass balances on gas exchange and nutrient uptake. One study comparing 260	  
the performance of a commercially available HFB called the ‘Quantum Cell Expansion System’ (from 261	  
Terumo BCT) with a static T-flask control for a modified human embryonic stem cell (hESC) line 262	  
showed that despite achieving a larger cell count whilst utilising an equivalent of 15% of the T-flask 263	  
growth medium, the HFB system achieved a lower cell viability (93-94%) and a lower cell density 264	  
(18,000-34,000 cells cm-2) than the control (99%, 190,000 cells cm-2) (Roberts et al. 2012). The 265	  
viability of the cells in the HFB was 93.5%, identical to that advertised by the manufacturer when 266	  
growing Mesenchymal Stem Cells (MSC) (Nguyen et al. 2012). This level of viability was linked to 267	  
longer exposure to lactate which was present in the HFB in higher concentrations at lower flow rates, 268	  
causing moderate acidic conditions which has been shown to affect hESC growth (Chen and Palmer 269	  
2010). Increased flow rates through the reactor should mitigate stagnant conditions occurring. 270	  
However this would need to be balanced with ensuring the subsequent high shear rates do not strip the 271	  
cells from their scaffold (Titmarsh et al. 2011), or other modifications such as pore size and porosity.  272	  
In a more general sense, bioreactors typically fail to meet cell number and functional requirements 273	  
because they provide unsuitable conditions for either the initial cell attachment or for the subsequent 274	  
cell expansion. They are also much less sophisticated than the conditions found in vivo, with some 275	  
aspects being much too elaborate for a bioreactor to control. 276	  
 277	  
Conclusion 278	  
It is apparent from the studies reviewed here that the versatility of HFB design and their ability to 279	  
expand a variety of cell types bodes well for their application in cell therapies, where mass production 280	  
of cells is required for regular clinical use, and in vitro models, to reduce reliance upon animal 281	  
experimentation. However, further study is required in both the understanding of the cellular 282	  
interactions with the bioreactor and subsequent modification of the culture environment to ensure that 283	  
there is homogeneity in the cell population. It is undisputable that HFBs provide the highest 284	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theoretical culture efficiency based on surface area to volume ratio. HFBs are scalable and applicable 285	  
to the culture of any cell type although are more suited to adherent cells and those from vascularised 286	  
tissues. The product can be a population of cells removed by trypsin, or a single solid construct 287	  
removed in its entirety from the module. A number of commercial HFBs are available although there 288	  
is no standard operating procedure and optimal operation has not yet been achieved. The design and 289	  
operation is specific to the cell type and end-use, and all aspects from hollow fibre material to 290	  
pressure gradients and flow configuration need to be considered. HFBs have been successfully used 291	  
for a range of tissues and this review suggests there is considerable interest and reason in continuing 292	  
to explore and optimise their application for tissue engineering. 293	  
 294	  
References 295	  
Bellis SL. (2011). Advantages of RGD peptides for directing cell association with biomaterials. 296	  
Biomaterials 32:4205-4210. 297	  
Bernstein HS, Srivastava D. (2012). Stem cell therapy for cardiac disease. Pediatr. Res. 71(4):491-298	  
499. 299	  
Burke ZD, Tosh D. (2006). The Wnt/beta-catenin pathway: master regulator of liver zonation? 300	  
Bioessays 28(11):1072-1077. 301	  
Chen G, Palmer AF. (2009). Hemoglobin-Based Oxygen Carrier and Convection Enhanced Oxygen 302	  
Transport in a Hollow Fiber Bioreactor. Biotechnol. Bioeng. 102(6):1603-1612. 303	  
Chen G, Palmer AF. (2010). Hemoglobin Regulates the Metabolic, Synthetic, Detoxification, and 304	  
Biotransformation Functions of Hepatoma Cells Cultured in a Hollow Fiber Bioreactor. 305	  
Tissue Eng. Part A 16(10):3231-3240. 306	  
	   	   13	  
	  
	  
Davidson AJ, Ellis MJ, Chaudhuri JB. (2012). A theoretical approach to zonation in a bioartificial 307	  
liver. Biotechnol. Bioeng. 109:234-243. 308	  
De Bartolo L, Morelli S, Bader A, Drioli E. (2002). Evaluation of cell behaviour related to physico-309	  
chemical properties of polymeric membranes to be used in bioartificial organs. Biomaterials 310	  
23:2485-97. 311	  
Ellis M, Jarman-Smith M, Chaudhuri JB. (2005). Bioreactor Systems for Tissue Engineering: A Four-312	  
Dimensional Challenge. In: Chaudhuri J, Al-Rubeai M, (ed) Bioreactors for Tissue 313	  
Engineering, Springer, Netherlands, pp 1-18. 314	  
Ellis MJ, Chaudhuri JB. (2007). Poly(lactic-co-glycolic acid) Hollow Fibre Membranes for use as a 315	  
Tissue Engineering Scaffold. Biotechnol. Bioeng. 96:177-187. 316	  
Ellis MJ, Chaudhuri JB. (2008). Human bone derived cell culture on PLGA flat sheet membranes of 317	  
different lactide : glycolide ratio. Biotechnol. Bioeng. 101(2):369-377. 318	  
FiberCell. (2014). Hollow fiber bioreactors and related products. 319	  
http://www.nbsbio.co.uk/downloads/fibercell_brochure.pdf . Accessed 20 May 2014 320	  
Gautier A, Ould-Dris A, Dufresne M, Paullier P, Von Harten B, Lemke H-D, Legallais C. (2009). 321	  
Hollow fiber bioartificial liver: Physical and biological characterization with C3A cells. 322	  
Journal of Membrane Science 341:203-213. 323	  
Gerecht-Nir S, Cohen S, Ziskind A, Itskovitz-Eldor J. (2004). Three-dimensional porous alginate 324	  
scaffolds provide a conducive environment for generation of well-vascularized embryoid 325	  
bodies from human embryonic stem cells. Biotechnol. Bioeng. 88(3):313-320. 326	  
Grek CL, Newton DA, Qiu YZ, Wen XJ, Spyropoulos DD, Baatz JE. (2009). Characterization of 327	  
alveolar epithelial cells cultured in semipermeable hollow fibers. Experimental Lung 328	  
Research 35(2):155-174. 329	  
	   	   14	  
	  
	  
Gundersen SI, Chen G, Powell HM, Palmer AF. (2010). Hemoglobin Regulates the Metabolic and 330	  
Synthetic Function of Rat Insulinoma Cells Cultured in a Hollow Fiber Bioreactor. 331	  
Biotechnol. Bioeng. 107(3):582-592. 332	  
Hoesli CA, Luu M, Piret JM. (2009). A Novel Alginate Hollow Fiber Bioreactor Process for Cellular 333	  
Therapy Applications. Biotechnol. Prog. 25(6):1740-1751. 334	  
Jacobs T, Morent R, Geyter N, Dubruel P, Leys C. (2012). Plasma Surface Modification of 335	  
Biomedical Polymers: Influence on Cell-Material Interaction. Plasma Chemistry and Plasma 336	  
Processing 32:1039-1073. 337	  
Nguyen K, Brecheisen BS, Peters R, Startz T, Vang B, Baila S. (2012). Automated Expansion of 338	  
Human Mesenchymal Stem Cells from  Precultured Cells Using the Quantum Cell Expansion 339	  
System. Online: Terumo BCT. 340	  
Niemeyer P, Fechner K, Milz S, Richter W, Suedkamp NP, Mehlhorn AT, Pearce S, Kasten P. (2010). 341	  
Comparison of mesenchymal stem cells from bone marrow and adipose tissue for bone 342	  
regeneration in a critical size defect of the sheep tibia and the influence of platelet-rich 343	  
plasma. Biomaterials 31:3572-3579. 344	  
Nold P, Brendel C, Neubauer A, Bein G, Hackstein H. (2013). Good manufacturing practice-345	  
compliant animal-free expansion of human bone marrow derived mesenchymal stroma cells 346	  
in a closed hollow-fiber-based bioreactor. Biochemical and Biophysical Research 347	  
Communications 430:325-230. 348	  
Oh HI, Ye SH, Johnson CA, Woolley JR, Federspiel WJ, Wagner WR. (2010). Hemocompatibility 349	  
Assessment of Carbonic Anhydrase Modified Hollow Fiber Membranes for Artificial Lungs. 350	  
Artificial Organs 34:439-442. 351	  
	   	   15	  
	  
	  
Oo ZY, Deng RS, Hui M, Ni M, Kandasamy K, Bin Ibrahim MS, Ying JY, Zink D. (2011). The 352	  
performance of primary human renal cells in hollow fiber bioreactors for bioartificial kidneys. 353	  
Biomaterials 32:8806-8815. 354	  
Ott M, Ballermann B. (1995). Shear stress-conditioned, endothelial cell-seeded vascular grafts: 355	  
improved cell adherence in response to in vitro shear stress. Surgery 117:334-339. 356	  
Patzer JF. (2004). Oxygen consumption in a hollow fiber bioartificial liver-revisited. Artificial Organs 357	  
28(1):83-98. 358	  
Roberts I, Baila S, Rice RB, Janssens ME, Nguyen K, Moens N, Ruban L, Hernandez D, Coffey P, 359	  
Mason C. (2012). Scale-up of human embryonic stem cell culture using a hollow fibre 360	  
bioreactor. Biotechnol. Lett. 34(12):2307-2315. 361	  
Seliktar D. (2012). Designing Cell-Compatible Hydrogels for Biomedical Applications. Science 362	  
336:1124-1128. 363	  
Shin SR, Jung SM, Zalabany M, Kim K, Zorlutuna P, Kim SB, Nikkhah M, Khabiry M, Azize M, 364	  
Kong J and others. (2013). Carbon-Nanotube-Embedded Hydrogel Sheets for Engineering 365	  
Cardiac Constructs and Bioactuators. Acs Nano 7:2369-2380. 366	  
Shipley RJ, Davidson AJ, Chan K, Chaudhuri JB, Waters SL, Ellis MJ. (2011). A Strategy to 367	  
Determine Operating Parameters in Tissue Engineering Hollow Fiber Bioreactors. 368	  
Biotechnol. Bioeng. 108(6):1450-1461. 369	  
Shipley RJ, Waters SL, Ellis MJ. (2010). Definition and Validation of Operating Equations for 370	  
Poly(Vinyl Alcohol)-Poly(Lactide-Co-Glycolide) Microfiltration Membrane-Scaffold 371	  
Bioreactors. Biotechnol. Bioeng. 107(2):382-392. 372	  
	   	   16	  
	  
	  
Simaria AS, Hassan S, Varadaraju H, Rowley J, Warren K, Vanek P, Farid SS. (2014). Allogeneic 373	  
Cell Therapy Bioprocess Economics and Optimization: Single-Use Cell Expansion 374	  
Technologies. Biotechnol. Bioeng. 111(1):69-83. 375	  
Soardi CM, Spinato S, Zaffe D, Wang HL. (2011). Atrophic maxillary floor augmentation by 376	  
mineralized human bone allograft in sinuses of different size: an histologic and 377	  
histomorphometric analysis. Clinical Oral Implants Research 22:560-566. 378	  
Spectrum Laboratories . (2012). CELLMAX Hollow FIber Bioreactors - A Low Cost Alternative to 379	  
Conventional Cell Culture Methods. https://webshop.fishersci.com/webfiles/uk/web-380	  
docs/CELLMAX.PDF . Accessed 20 May 2014 381	  
Sullivan JP, Gordon JE, Bou-Akl T, Matthew HW, Palmer AF. (2007). Enhanced oxygen delivery to 382	  
primary hepatocytes within a hollow fiber bioreactor facilitated via hemoglobin-based oxygen 383	  
carriers. Artificial cells, blood substitutes, and immobilization biotechnology 35(6):585-606. 384	  
Sun T, Jackson S, Haycock JW, MacNeil S. (2006). Culture of skin cells in 3D rather than 2D 385	  
improves their ability to survive exposure to cytotoxic agents. Journal of Biotechnology 386	  
122:372-381. 387	  
Titmarsh D, Hidalgo A, Turner J, Wolvetang E, Cooper-White J. (2011). Optimization of Flowrate for 388	  
Expansion of Human Embryonic Stem Cells in Perfusion Microbioreactors. Biotechnol. 389	  
Bioeng. 108(12):2894-2904. 390	  
Torres J, Tamimi F, Alkhraisat MH, Prados-Frutos JC, Rastikerdar E, Gbureck U, Barralet JE, Lopez-391	  
Cabarcos E. (2011). Vertical bone augmentation with 3D-synthetic monetite blocks in the 392	  
rabbit calvaria. Journal of Clinical Periodontology 38:1147-1153. 393	  
Usuludin SBM, Cao X, Lim M. (2012). Co-culture of stromal and erythroleukemia cells in a perfused 394	  
hollow fiber bioreactor system as an in vitro bone marrow model for myeloid leukemia. 395	  
Biotechnol. Bioeng. 109(5):1248-1258. 396	  
	   	   17	  
	  
	  
Vermonden T, Censi R, Hennink WE. (2012). Hydrogels for Protein Delivery. Chemical Reviews 397	  
112:2853-2888. 398	  
Williams DJ, Thomas RJ, Hourd PC, Chandra A, Ratcliffe E, Liu Y, Rayment EA, Archer JR. (2012). 399	  
Precision manufacturing for clinical-quality regenerative medicines. Philos. Trans. R. Soc. A-400	  
Math. Phys. Eng. Sci. 370(1973):3924-3949. 401	  
Yamazoe H, Iwata H. (2006). Efficient generation of dopaminergic neurons from mouse embryonic 402	  
stem cells enclosed in hollow fibers. Biomaterials 27:4871-4880. 403	  
Zeilinger K, Schreiter T, Darnell M, Soderdahl T, Lubberstedt M, Dillner B, Knobeloch D, Nussler 404	  
AK, Gerlach JC, Andersson TB. (2011). Scaling Down of a Clinical Three-Dimensional 405	  
Perfusion Multicompartment Hollow Fiber Liver Bioreactor Developed for Extracorporeal 406	  
Liver Support to an Analytical Scale Device Useful for Hepatic Pharmacological In Vitro 407	  
Studies. Tissue Eng. Part C-Methods 17(5):549-556. 408	  
Zhang S, Liu T, Chen L, Ren M, Zhang B, Wang Z, Wang Y. (2012). Bifunctional polyethersulfone 409	  
hollow fiber with a porous, single-layer skin for use as a bioartificial liver bioreactor. Journal 410	  
of Materials Science Materials in Medicine 23:2001-2011. 411	  
Zhou X, Rowe RG, Hiraoka N, George JP, Wirtz D, Mosher DF, Virtanen I, Chernousov Ma, Weiss 412	  
SJ. (2008). Fibronectin fibrillogenesis regulates three-dimensional neovessel formation. 413	  
Genes & Development 22:1231-1243. 414	  
	  415	  
 416	  
 417	  
 418	  
	   	   18	  
	  
	  
Table 1 Cellular expansion using a HFB system 419	  
Cell Type 
Seeding Expanded 
References Number 
(cells) 
Density 
(cells cm-2) 
Number 
(cells) 
Density 
(cells cm-2) 
Fold increase 
Visual 
depiction 
Other analysis (e.g. 
biochemical) 
Lymphocyte 
Human (primary 
tumour 
infiltrating) 
 
Human 
(primary) 
1 x 109 
 
 
 
1.92 x 108 
- 
 
 
 
- 
1 x 1011 
(dose 
reached) 
 
- 
- 
 
 
 
- 
- 
 
 
 
- 
- 
 
 
 
- 
 
Increased lactate 
(14d) 
 
 
Increased glucose 
uptake and lactate 
(8d) 
(Malone et al. 
2001) 
 
 
(Curcio et al. 
2012) 
Embryonic stem 
cell 
Human 
(Shef3) 
6 x 107 ~ 3 x 103 
3.83 x 109 
(8d) 
7.08 x 109 
(8d) 
1.8 x 104 
 
3.4 x 104 
- 
 
- 
- 
 
- 
Increased lactate 
(52h) 
(Roberts et al. 
2012) 
Mesenchymal 
stem cell 
Human (primary 
bone marrow) 
2 x 106 
 
3.5 x 106 
 
5 x 106 
 
7.6 x 106 
- 
 
- 
 
- 
 
- 
1.87 x 107 
(6d) 
5 x 107 
(11d) 
9.8 x 107 
(13d) 
1.72 x 107 
(13d) 
- 
 
- 
 
- 
 
- 
9.4 
 
14.2 
 
20 
 
2.3 
- 
 
- 
 
- 
 
- 
Increased glucose 
uptake and lactate 
(25d) 
(Nold et al. 
2013) 
- 5 x 103 - - 
25 
(DNA 
concentration) 
- 
Increased DNA 
concentration 
(120h, 168h) 
(Morgan et al. 
2007) 
Embryonic liver 
cell 
Rat 
(RLC-18) 
- 1 x 104 - - 
1.97 
(14d) 
SEM 
(8d, 14d) 
- 
(Salerno et al. 
2013) 
Bone marrow 
stromal cell 
Human 
(HS-5) 
1 x 108 4.76 x 104 
4.42 x 108 
(28d) 
2.11 x 105 
 
- - 
Increased glucose 
uptake and protein 
concentration 
(28d) 
(Usuludin et 
al. 2012) 
Haematopoietic 
cell 
Human 
(K562 co-culture 
with HS-5) 
5 x 105 - - - 
3130 
(14d) 
- - 
Adipose stem cell 
Human 
(primary) 
- 1 x 105 - - - 
Live-dead 
stain 
(3d, 7d) 
Increased DNA 
concentration 
(1d, 3d, 7d) 
(Diban et al. 
2013) 
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Table 2 Cellular differentiation using a HFB system 424	  
Cell Type Differentiated Cell References 
Haematopoietic stem cell Human 
Neutrophil 
Erythrocyte 
Lymphocyte 
(Housler et al. 2012) 
Embryonic stem cell Mouse 
Dopaminergic neuron 
 
Hepatocyte 
(Yamazoe and Iwata 2006) 
 
(Amimoto et al. 2011) 
Induced pluripotent stem cell Mouse Hepatocyte (Amimoto et al. 2011) 
Mesenchymal stem cell Sheep Osteoblast (De Napoli et al. 2011) 
Embryonic liver cell Rat Hepatocyte (Salerno et al. 2013) 
	  425	  
	  426	  
	  427	  
	  428	  
	  429	  
	  430	  
	  431	  
	  432	  
	  433	  
	  434	  
	  435	  
	  436	  
	  437	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Table 3 Bioreactor design configurations and their capacities (Ellis et al. 2005). 439	  
Configuration Media change Mixing conditions Tissue development Culture dimensions 
Size to grow 
an organ 
Tissue culture flask Batch 
Poorly mixed 
No shear 
Diffusion 
2D sheet 
290 cm2 L-1 
1 x 105 cells ml-1 
10-1000 L 
Stirred tank Batch or continuous 
Well mixed 
Shear 
Convection 
2D or 3D 
2800 cm2 L-1 
5 x 105 cells ml-1 
2-200 L 
Packed beds 
Continuous feed 
(perfusion) 
Well mixed 
Shear 
Convection 
3D 
18,000 cm2 L-1 
2.5 x 106 cells ml-1 
0.4-40L 
Fluidised bed 
Continuous feed 
(perfusion) 
Well mixed 
Shear 
Convection 
3D 
25,000-70,000 cm2 L-1  
5-6 x 106 cells ml-1 
0.2-20L 
Membrane 
bioreactors 
Continuous feed 
Well mixed 
No Shear or Shear 
Convection and 
diffusion 
3D 
100,000-200,000 cm2 L-1 
2 x 108 cells ml-1 
0.05-0.5L 
 440	  
 441	  
 442	  
 443	  
 444	  
 445	  
 446	  
 447	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FIGURE LEGENDS 449	  
 450	  
Figure 1 – Cell attachment and growth in a hollow fibre membrane. Cells can be seeded and 451	  
consequently cultured on the lumen surface or the external surface of the membrane wall, or 452	  
encapsulated in a gel in the extracapillary space. Cells could be encapsulated within the fibre wall 453	  
itself, or allow migration if the pores are large enough, however such an approach is not covered in 454	  
this review. Typical fibre outer diameter ranges between 500 – 1000 µm with a wall thickness of 200 455	  
µm. Figure not to scale. 456	  
Figure 2 – The different operational configurations of a hollow fibre bioreactor. A-D have retentate 457	  
streams, the permeate flux can be prescribed by applying back pressure on the retentate stream; E-H 458	  
are ‘dead-end’ with the retentate stream shut off (H is of no use in practice but shown for 459	  
completeness); (I) Starling flow for which the extracapillary ports are shut off. A, C, E, G & I show 460	  
co-current configurations, and B, D, F & H show counter current configurations.  461	  
Figure 3 – Common steps for performing cell culture in a hollow fibre bioreactor. 462	  
 463	  
 464	  
 465	  
 466	  
 467	  
 468	  
 469	  
 470	  
 471	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Intra-luminal cell attachment
External surface cell attachment
Cell growth in gel around the hollow fibre
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Figure 3 494	  
 495	  
 496	  
Sterilisation
• Autoclave bioreactors and other equipment.
• Soak bioreactor with antibiotic/antimitotic solution for 1 hour.
• Fibre sterilisation methods depend on the material and its macro-
architecture.
Cell 
Seeding
• Soak fibres in complete media for half an hour.
• Seed directly onto the fibres within the reactor.
• Can also be seeded as part of a gelling solution such as alginate.
Transport
• HFBs moved from the sterile biohood to non-sterile incubator.
• Pumps, tubing and other ancillary equipment should be set up prior to 
transportation.
Cell 
Attachment
• Cells can be allowed to settle onto the fibres statically.
• HFBs can also be attached to a rotating device to improve cell  
attachment on fibres.
Cell 
Expansion
• After attachment cell media is flowed through the lumen of the fibres.
• A secondary feed can be applied as a counter current through the ECS.
• A suitable back pressure must also be selected.
Differentiation 
(optional)
• Cell  medium may need to be changed to allow differentiation into 
specific cell types.
• An inlet valve should be placed to facilitate this.
• Physical reactor conditions may also need to be altered. 
Product 
Removal
• Remove cells from the fibres using trypsin via side port.
• Whole construct within the HFB can  also be removed if necessary.
